Mitopharmacogenomics: The Power of Mitochondria Over Your Medicine Cabinet

Did you know that your mitochondrial DNA (mtDNA) can determine which drugs heal you and which ones harm you?

MtDNA is the great forgotten player in pharmacogenetics, but it can determine why a drug that saves lives in some people becomes toxic in others!

Below you will find how small changes in this genetic code shape your response to common medications:

1. Antibiotics: Breaking the Silence

Aminoglycosides (AGs), such as gentamicin or neomycin, are antibiotics used to treat severe bacterial infections. They act by inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit. The m.1555A>G mutation, located in the 12S rRNA gene, alters the human mitochondrial ribosome, making it more similar to its bacterial counterpart and therefore susceptible to aminoglycosides. The result is a toxic side effect: ototoxicity, leading to hearing loss upon exposure to these drugs.

 

2. Anesthesia and the Metabolic “Blackout”

Volatile anesthetics and some neuromuscular blockers rely on mitochondria to sustain energy production under physiological stress. Certain mtDNA variants can increase sensitivity to volatile anesthetics, raising the risk of lactic acidosis or organ dysfunction during surgery.

 

3. Antiepileptic Drugs and Sudden Liver Failure

Valproic acid (VPA) is a widely used antiepileptic drug but has a well-known mitochondrial toxic profile, as it inhibits β-oxidation. The liver, which is highly dependent on mitochondrial function, is particularly vulnerable. Mutations in the gene encoding mitochondrial DNA polymerase (POLG) reduce mtDNA copy number, severely affecting energy-demanding tissues such as the liver and brain. In patients carrying POLG mutations, VPA can be fatal due to hepatic mitochondrial collapse.

 

4. Antiretrovirals (HIV) and Chemotherapy: The Cost of Energy

Some HIV treatments and certain chemotherapeutic agents directly impair mtDNA replication. As a consequence of mitochondrial toxicity, patients may develop extreme fatigue, muscle weakness (myopathy), and nerve damage (neuropathy). In these cases, it is not only the disease—the treatment itself contributes to the damage.